Invivyd IVVD 深 沪
等待开盘 05-19 09:30:00 美东时间
1.13
-0.080
-6.61%
华盛通- 最 高1.23
- 今 开1.21
- 成交量 481.15万股
- 最 低 1.12
- 昨 收 1.21
- 总市值 3.33亿
- 52周最高 3.0699
- 市盈率 静 --
- 换手率 1.63%
- 52周最低 0.483
- 委 比 63.82%
- 总股本 2.95亿
- 历史最高 78.82
- 量 比 0.98
- 振 幅 9.09%
- 历史最低 0.3546
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
今天 10:55
BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target
BTIG analyst Thomas Shrader reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $10 price target.
05-18 17:55
Invivyd PEMGARDA营收增长22% VYD2311关键试验招募临近完成
一季度业绩：产品收入稳健增长 Invivyd近日公布2026年第一季度财报。数据显示，公司核心产品PEMGARDA实现净产品收入1370万美元，较上年同...
05-15 03:27
Invivyd Reports Q1 2026 Results: Full Earnings Call Transcript
On Thursday, Invivyd (NASDAQ:IVVD) discussed first-quarter financial results du...
05-14 21:35
Invivyd Q1 FY26 net loss widens to $41.4 million; revenue rises to $13.74 million
Invivyd Q1 FY26 net loss widens to $41.4 million; revenue rises to $13.74 million Invivyd posted a net loss of USD 41.4 million for three months ended March 31, 2026, widening from USD 16.29 million a year earlier. Revenue rose 21.58% to USD 13.74 million, while research and development expense near
05-14 19:19
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Invivyd Q1 EPS $(0.13) Misses $(0.07) Estimate, Sales $13.744M Miss $18.050M Estimate
Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.07) by 85.71 percent. This is a 7.14 percent increase over losses of $(0.14) per share from the same
05-14 19:05
Invivyd EVADE Trial Data Reveals Monoclonal Antibody VYD2311 Demonstrates Minimal Tolerability Issues Versus COVID mRNA Vaccination
Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issuesResults allow for comparison to contemporary
05-11 19:13
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
Marc Elia, Chairman of Invivyd, Inc., will speak at the POLITICO Health Care Summit on April 21, discussing viral disease prevention and the role of monoclonal antibodies. The event will stream live from 9:00 AM ET to 1:00 PM ET, with Elia's session at 11:30 AM ET. Invivyd focuses on developing monoclonal antibodies to improve health outcomes beyond vaccines. Register for the live stream at politicoshealthcaresummit.splashthat.com/CMS.
04-20 11:01
美股牛股 | ZNTL飙升60%，卵巢癌临床试验获重大突破；IVVD大涨31%
ZNTL飙升60%，卵巢癌临床试验获重大突破；IVVD大涨31%，就儿科临床研究与FDA达成一致；EOSE大涨近30%，Q1财报强劲，营收创新高>>
04-10 19:22
